70.42USD+2.15%Mkt Cap: 2.45B USDP/E: 16.24Last update: 2026-05-26
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides…
Industry Peers
Medical Devices151.38BUSDP/E 24.3
119.84BUSDP/E 36.2
86.12BUSDP/E 24.2
54.95BSEKP/E 101.9
53.92BSEKP/E 22.9
52.13BDKKP/E 22.1
50.54BUSDP/E 47.4
39.31BEURP/E 18.6
Indicators:|
Key Statistics
Company
Market Cap2.45B USD
Enterprise Value2.78B USD
Revenue (TTM)635.89M USD
Gross Profit362.81M USD
Net Income (TTM)190.29M USD
Revenue/Share18.62 USD
Last Price70.42 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees898
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)16.24
P/E (Forward)19.37
PEG—
EV/EBITDA22.19
EV/Revenue4.37
P/S3.74
P/B4.99
EPS (TTM)4.37
EPS (Forward)3.55
52W Range
60.1011% of range156.00
52W High156.00 USD
52W Low60.10 USD
Profitability
Gross Margin59.92%
Oper. Margin7.65%
EBITDA Margin19.71%
Profit Margin31.43%
ROE40.22%
ROA17.81%
Growth
Revenue Growth21.20%
Earnings Growth-71.50%
Cash Flow & Leverage
Operating CF192.84M USD
CapEx (TTM)59.25M USD
FCF Margin17.11%
FCF Yield4.44%
Net Debt401.68M USD
Net Debt/EBITDA3.20
Balance Sheet
Debt/Equity1.10
Current Ratio6.74
Quick Ratio6.01
Book Value/Sh13.81 USD
Cash/Share13.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)117.89 USD
Target Range85.00 USD – 142.00 USD
# Analysts9
Ownership
Shares Out.34.56M
Float33.45M
Insiders3.29%
Institutions109.93%
Short Interest
Short Ratio9.3d
Short % Float37.55%
Short % Out.24.07%
Shares Short8.32M
Short (prev mo.)8.03M
Technical
SMA 5098.73 (-28.7%)
SMA 200119.73 (-41.2%)
Beta2.06
S&P 52W Chg28.31%
Avg Vol (30d)1.55M
Avg Vol (10d)1.82M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—